10.05.2023 13:19:45

Teva Pharma Reaffirms FY23 Outlook - Update

(RTTNews) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.

For fiscal 2023, the company still projects adjusted earnings in a range of $2.25 to $2.55 per share on revenues between $14.8 billion and $15.4 billion.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.40 per share on revenues of $15.06 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel